We are committed to developing and commercializing products that provide meaningful clinical improvements over the current standard of care in treating psychiatry related disorders.
We currently supply two antidepressant products in the US. Each product reduces the number of pills a patient needs to take to achieve their daily dosing requirement.
Our lead pipeline product EDG004 is currently enrolling patients in its pivotal Phase III clinical trial for the treatment of Generalized Anxiety Disorder in adults.
April 2015: US Patent issued for our our product candidate EDG004.